STUDY SHINES LIGHT ON GUT MICROBIOME IN COLON CANCER. Interactions between host microRNAs and the gut microbiota in colorectal cancer. Yuan C, Burns M, Subramanian S*, Blekhman R*. Host-microRNA-microbiome interactions in colorectal cancer. ![]() microRNA-Mediated Tumor-Microbiota Metabolic Interactions in Colorectal Cancer. Welcome summer students, Maddie Kehoe, Krishna Mishra and Nile Liu for joining our lab May. student, MICaB) and undergraduate researcher Jessica Faulkner for joining our lab August. Welcome rotating student Jacob Myers (Ph.D. the overall response rate in addition to overcoming resistance and enhance. Mucosal microbiota and metabolome along the intestinal tracts reveals location specific relationship. Congratulations to Lisa Basso on her new job at MD Biosciences October. Subbaya Subramanian Department of Surgery, University of Minnesota Medical. Yuan C, Graham ML, Staley C, Subramanian S*. Results from this study will elucidate the underlying mechanisms of host-microbiome interactions in CRC and will provide insights into the development of novel treatment strategies. In light of these evidence, we are testing the hypothesis that a positive feedback loop exists in CRC in which preexisting dysbiosis initially drives the expression of certain miRNAs in the colon epithelium, which are then released into the colon lumen and in turn affect the composition of the gut microbiome, leading to additional dysbiosis. ![]() ![]() Previous publications have elucidated how the microbiome could affect miRNA expression in CRC, but how CRC could affect the microbiome is not yet understood, even though host genetics is known to shape the microbiome. Part of the reason is the complex interplay between the colon epithelium, the microbiome, and the immune system. In the past decade, with the advancement of high-throughput “omics” technologies, it has become clear that the microbiome plays an essential role in driving the pathogenesis of CRC however, the mechanisms that underlie host-microbiome interactions in CRC have yet to be elucidated. And most of the improvement in survival is due to increased screening, which has identified more cases of CRC in earlier stages. Although the 5-year survival rate has been rising over the past few decades, it is still low at about 65%. The current standard of care for colorectal cancer (CRC) involves chemotherapies developed more than 50 years ago.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |